|
|
|
|
|
| April 1 ,
2010 | ISSUE NUMBER 142 VOL 8 |
Sales
Rx Sales Jump 5.1 Percent to $300 Billion in 2009
IMS Health reports a nice increase in prescription sales from 2008 to 2009, even with a recession in full swing. That said, numbers are still well below the historic sales of a few years back, and it’s anyone’s guess if they will reach that high again.
Deals
GSK Inks $1.5 Billion Collaboration Deal with Isis
Glaxo and Isis formed a billion-dollar alliance to create new RNA therapies for the rare and infectious disease segment. The key ingredient in the deal is Isis’ drug discovery platform. Could it be a game changer? GSK thinks so.
Legal
Judge Spikes Myriad Genetic’s Control of Genes
Score one for nature. A US district court judge on Monday declared that pharma companies can’t patent individual genes because they are not, in fact, creating them.
New & Noteworthy
The New Merck's Move on Emerging Markets
Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?
Call for Nominations
Pharmaceutical Executive¹s Emerging Pharma Leadership Award
The pharma industry is facing some tough times‹and the old way of doing things just won¹t work. So just who are the new leaders steering the industry though its most difficult challenges? Which executives are revamping the industry‹through pure innovation‹to remake it for the 21st century?
These emerging leaders are vital to the future of the industry, and you can help ensure that they get the recognition they deserve. Fill out your nomination today! |
|
 |
 |
|  Novasys Medical hired Scott Cramer as president and CEO. He had been president and CEO of Bacchus Vascular. // OncoGenex Pharmaceuticals appointed Jack Goldstein and H. Stewart Parker to its board.
// Clanotech added Bo Oberg to its board. // Tianyin Pharmaceutical elected James Jiayuan Tong to its board and named him CFO and chief business and development officer.
// Hycor Biomedical appointed Dick Aderman president and CEO.
// Idenix Pharmaceuticals added Tamar Howson to its board.
//
|
|
|
|
 |
|
 |
|
 |
| If you plan to enter emerging markets over the next 3 years, what will be your primary entry strategy? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
